We continue on our journey through early stage breast cancer, this time turning our attention to HER2+ disease. There is a lot of data in this episode, as you will both hear and see. To make this easier, we highlight key takeaways to make understanding this even easier. Content: - What is HER2? - Discovery of trastuzumab- Data for use of trastuzumab in adjuvant and neoadjuvant setting- Data for use of pertuzumab in adjuvant and neoadjuvant setting - Data and use of trastuzumab emtansine (TDM-1) in the adjuvant setting- Management of HER2+ stage I breast cancer- Highlights of key trials that shape the paradigm of management- Our approach to management ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related